RA Pathogenesis, Patient Goals, and Traditional Treatment Course for Moderate-to-Severe Disease
Rheumatoid arthritis (RA) is a chronic, inflammatory disease affecting 1% of the population. If left untreated or undertreated, patients with RA can suffer from joint destruction as well as a wide array of debilitating extra-articular, systemic effects. This web-based interactive enduring activity will provide participants with the opportunity to optimize the treatment of patients with RA by assessing new data and recent treatment recommendations for disease-modifying anti-rheumatic drugs (DMARDs) for those with moderate to severe RA. Participants will also explore the importance of early and aggressive treatment and learn to select appropriate, individualized initial and escalation therapies for patients with RA. This will enable them to better identify those RA patients in whom an IL-6 inhibitor, or other non-tumor necrosis factor inhibitor, may be an appropriate strategy.
The goal of this activity is to provide rheumatologists and other healthcare professionals with valuable clinical insights in assessing new and emerging therapies for patients with RA, including IL-6 inhibitors, and explore the effective use of these newer therapies in clinical practice.
This activity is intended for rheumatologists and other healthcare providers (physicians, nurse practitioners, and physicians’ assistants) who treat patients with RA.
Upon completion of this activity, participants will be better able to do the following:
- DISCUSS the importance of early and aggressive treatment of RA.
- ASSESS new data and recent treatment recommendation updates regarding the use of DMARDs for moderate to severe RA.
- SELECT appropriate, individualized initial and escalation therapies for patients with RA.
Roy Fleischmann, MD, MACR (Chair)
Bernard Combe, MD, PhD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
Roy Fleischmann, MD, MACR
Consultant/Advisor: Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Janssen Global Services, LLC, Pfizer Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, UCB, Inc.
Grant/Research Support: Amgen Inc, AbbVie Inc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Pfizer Inc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, UCB, Inc.
Speakers’ Bureau: Pfizer Inc.
Bernard Combe, MD, PhD
Consultant/Advisor: Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Janssen Global Services, LLC; MSD & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; UCB, Inc.
Grant/Research Support: F. Hoffmann-La Roche Ltd; Pfizer Inc.; UCB, Inc.
Speakers’ Bureau: Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; MSD & Co., Inc.; Pfizer Inc.; Sanofi; UCB, Inc.
Non-faculty: Christina M. Ohnsman, MD; Jessica Marshall, PhD; Lou Settembrino; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Supported by independent educational grants from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
An application has been made to the EACCME®
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Genzyme, a Sanofi Company and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician